Trial · NCT06937229
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Up to approximately Week 30 | |
| Secondary | Number of Participants With Adverse Events (AEs) | Up to approximately Week 30 | |
| Secondary | Number of Participants With Serious AEs (SAEs) | Up to approximately Week 30 | |
| Secondary | Number of Participants With TEAEs Leading to Study Withdrawal | Up to approximately Week 30 | |
| Secondary | Number of Participants With TEAEs Leading to Death | Up to approximately Week 30 | |
| Secondary | Number of Participants with Adverse Events of Special Interest (AESI) | Up to approximately Week 30 | |
| Secondary | Change From Baseline in Barnes Akathisia Rating Scale (BARS) | Up to approximately Week 26 | |
| Secondary | Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) | Up to approximately Week 26 | |
| Secondary | Change From Baseline in Body Weight | Up to approximately Week 26 | |
| Secondary | Change From Baseline in Body Mass Index (BMI) | Up to approximately Week 26 | |
| Secondary | Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Heart Rate (HR) | Up to approximately Week 30 | This includes measuring of HR, both supine and standing or seated and upon standing after 2 minutes. |
| Secondary | Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Blood Pressure (BP) | Up to approximately Week 30 | This includes measuring of systolic and diastolic BP, both supine and standing or seated and upon standing after 2 minutes. |
| Secondary | Number of Participants With Clinically Significant Changes in Laboratory Evaluations | Up to approximately Week 30 | |
| Secondary | Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) | Up to approximately Week 26 | |
| Secondary | Number of Participants With Suicidal Ideations as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS) | Up to approximately Week 30 | |
| Secondary | Number of Participants With Cognitive Impairment as Assessed by Mini-mental State Examination (MMSE) | Up to approximately Week 26 | |
| Secondary | Number of Participants With Cognitive Impairment as Assessed by 13-item Variation of ADAS-Cog Scale (ADAS-Cog-13) | Up to approximately Week 26 | |
| Secondary | Change From Baseline in the Severity of Benign Prostatic Hyperplasia as Assessed by International Prostate Symptom Score (IPSS) | Up to approximately Week 26 | This analysis is done in male participants. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06937229/registered